Abstract:Objective To study the clinical effects of Cidan Capsules combined with mFOLFOX6 regimen in treatment of Bismuth-Corlette Ⅱ hilar cholangiocarcinoma. Methods Patients (82 cases) with Bismuth-Corlette Ⅱ hilar cholangiocarcinoma in NO.215 Hospital of Shaanxi Nuclear Industry from January 2010 to January 2014 were randomly divided into control and treatment groups, and each group had 41 cases. Patients in the control group were iv administered with 5-Fluorouracil Injection on the first day, 2 800 mg/m2 for 4 — 6 h, as well as iv administered with Calcium Folinate Injection 400 mg/m2, and with Oxaliplatin Injection85 mg/m2 added into 5％ glucose solution 500 mL for 3 h. Patients in the treatment group were po administered with Cidan Capsules on the basis of the control group, 5 grains/time, four times daily. Two weeks was a course of treatment, and patients in two groups were treated for 6 courses. After treatment, the short-term and long-term efficacy was evaluated, and the immune function, life quality and adverse actions in two groups before and after treatment were compared. Results After treatment, the objective reaction rate and clinical benefit rate in the control group were 73.1％ and 50.9％, which were significantly lower than 81.7％ and 62.5％ in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the survival rate of 1 year, 2 years, and 3 years, and OS in the treatment group were significantly higher than those in the control group (P<0.05). After treatment, the CD3+, CD4+, IgG, IgA and IgM levels in two groups were significantly increased (P<0.05), and the immune function in the treatment group was significantly better than that in the control group (P<0.05). After treatment for 5 and 6 courses of treatment, the KPS scores in control group were significantly higher than pretherapy (P<0.05). After treatment for 3, 4, 5, and 6 courses of treatment, the KPS scores in treatment group were significantly higher than pretherapy (P<0.05), and were significantly higher than that in the control group (P<0.05). During the treatment, the adverse reactions rate in the treatment group was significantly lower than that in the control group, with significant difference between two groups (P<0.05). Conclusions Cidan Capsules combined with m FOLFOX6 regimen in treatment of Bismuth-Corlette Ⅱ hilar cholangiocarcinoma can improve the immune function, lengthen the survival time and decrease the toxic and side effects.

Babaodan Capsule () Combined with Qingyi Huaji Formula () in Advanced Pancreatic Cancer-a Feasibility Study.

Identification of Bioactive Ingredients from Babaodan Using UPLC-QTOF-MS Analysis Combined with Network Pharmacology Guided Bioassays.

Retrospective Study of 232 Post-operative Patients with Pancreatic Cancer Treated by Modified Qingyi Huaji Formula Combined with Western Medicine

Survival Analysis on 64 Cases of Advanced Pancreatic Cancer Treated by Integrated Western and Traditional Chinese Medicine Mainly with Qingyi Huaji Formula

A Clinical Trial on the Effect of Qingyi Huaji Herbal Decoction Combined with Transcatheter Arterial Chemotherapy and Radiotherapy for Inoperable Pancreatic Cancer

Prognostic analysis of 190 elderly patients with pancreatic cancer treated by integrated traditional Chinese and Western medicine therapy

Prognostic analysis of 190 elderly patients with pancreatic cancer treated by integrated traditional Chinese and West-ern medicine therapy

Babaodan Inhibits Cell Proliferation and Metastasis and Enhances Anti-Tumor Effects of Camrelizumab by Inhibiting M2 Phenotype Macrophages in Hepatocellular Carcinoma

Research on prognostic factors in advanced pancreatic cancer treated by "Qingyi Huaji Formula"based on survival analysis

Clinical analysis on 20 cases of long term survival patients with advanced pancreatic cancer

Qingrehuashi Herbal Formula combined with high intensity focused ultrasound for treating advanced pancreatic cancer

Qingyihuaji Formula promotes apoptosis and autophagy through inhibition of MAPK/ERK and PI3K/Akt/mTOR signaling pathway on pancreatic cancer in vivo and in vitro

Qingyihuaji Formula Inhibits Progress of Liver Metastases from Advanced Pancreatic Cancer Xenograft by Targeting to Decrease Expression of Cyr61 and Vegf

Qingyihuaji Formula Inhibits Pancreatic Cancer and Prolongs Survival by Downregulating Hes-1 and Hey-1.

Babao Dan Reverses Multiple-Drug Resistance in Gastric Cancer Cells via Triggering Apoptosis and Autophagy and Inhibiting PI3K/AKT/mTOR Signaling

The therapeutic effects of Qing Re Hua Ji(QRHJ) decoction combined with HAI/TACE treating advanced pancreatic cancer: A randomize, control clinical study

Effect of Qingyi Huaji Decoction Combined with Gemcitabine on Apoptosis and Expression of Bcl-2 Protein of Pancreastic Cancer SW1990 in Vivo

A Retrospective Cohort Study on Treatment Oftiaogan-Bushen-xiaoji Recipe for the Patients with Advanced Breast Cancer

Integrating network pharmacology and experimental models to investigate the efficacy of QYHJ on pancreatic cancer

Clinical study on Cidan Capsules combined with mFOLFOX6 regimen in treatment of Bismuth-Corlette Ⅱ hilar cholangiocarcinoma

High expression of erythropoietin-producing hepatoma cell line-B2 (EphB2) predicts the efficiency of the Qingyihuaji formula treatment in pancreatic cancer CFPAC-1 cells through the EphrinB1-EphB2 pathway.